AlphAIAlphAI — Financial news for AI agents
northernnews.ca$ABCL

AbCellera Reports Q3 2026 Business Results

AbCellera (ABCL) reported Q3 2026 results, with revenue up to $10.6M from $9.0M in Q3 2025. Net loss narrowed to $40.8M from $57.1M. The company raised $200M, bringing total liquidity to $890M. Positive Phase 2 data for ABCL635 and Phase 1 data for ABCL575 were announced, along with three new pipeline programs.

Original reporting
northernnews.ca
Published Nov 9, 2026, 9:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AbCellera Reports Q3 2026 Business Results — source image
Source · northernnews.ca
Decision brief

The 30-second read

$ABCLBullishHigh
01

Why it matters

The earnings beat and trial success provide a dual catalyst for short‑term price appreciation.

02

Market read

First‑time disclosure of earnings, capital raise, and trial data creates immediate trading opportunity.

03

What to watch

The $200M raise may dilute existing shareholders and increase cash‑burn expectations.

Relevance 9/10Novelty 9/10Timing: today

Background

AbCellera is a clinical‑stage antibody discovery company focusing on women's health and oncology.

Company-level read

Ticker impact

$ABCLBullishHigh confidence
Context

AbCellera reported Q3 2026 results, raised $200M and disclosed positive Phase 2 data for ABCL635.

Expected impact

potential upside as market prices in the strong trial readout and expanded liquidity.

Evidence & confidence

The $200M capital raise improves balance sheet while Phase 2 efficacy data for a hot‑flash treatment is a material catalyst for a biotech.

Market effects

Sector

Biotech sector may see broader rally on positive late‑stage data.

Regional

North American biotech indices could gain modestly.

Global

Positive trial data adds confidence to antibody‑based therapeutics worldwide.

Counterpoint

What could challenge this read

If the Phase 2 data does not translate to later stages, the stock could be overbought.

Key entities

  • company
    AbCellera Biologics Inc.

    Clinical‑stage biotech reporting Q3 2026 results.

  • drug_candidate
    ABCL635

    Antibody showing positive Phase 2 results for menopausal hot flashes.

Read at source← All news

StoryAbCellera reports Q3 2026 results and breakthrough Phase 2 data for ABCL635

Also covered by

2 outlets

Related articles

$ABCLHighAI 9/10

AbCellera (ABCL) Q3 2026 Earnings Call Transcript

AbCellera (ABCL) reported Q3 2026 earnings, highlighting positive results for ABCL635 in treating women's health issues. The drug showed significant reduction in hot flashes and severity of symptoms compared to placebo. The company plans to advance ABCL635 into late-stage development in 2027 and is also exploring its use for cancer treatment-related hot flashes. Additionally, AbCellera announced a new program, ABCL992, and presented Phase I results for ABCL575.

finance.yahoo.com
$ABCLHighAI 9/10

AbCellera Q3 2026 slides: ABCL635 data sets new VMS efficacy bar

AbCellera (NASDAQ:ABCL) reported Q3 2026 results, highlighting positive Phase 2 data for ABCL635, its lead program for treating menopausal VMS. The company saw a net loss narrow to $41M and shares rose 5.22% to $12.50. ABCL635 showed significant efficacy in reducing VMS frequency and severity, with 37% of patients achieving complete symptom resolution. AbCellera plans to advance ABCL635 into late-stage trials in 2027 and expand into additional indications.

investing.com
$ABCLHigh

AbCellera Reports Q3 2026 Business Results

AbCellera Biologics Inc. (ABCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE AbCellera Reports Q3 2026 Business Results 11/9/2026 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars,

SEC EDGAR 8-K
$ABCLMed

Abcellera Biologics earnings on deck as ABCL635 takes spotlight

Abcellera Biologics Inc. reports Q3 earnings with expected loss of 17 cents per share on $6.21M revenue, down 31% YoY. Investors focus on ABCL635, its lead drug, after Phase 2 data showed 83% reduction in hot flashes. Analysts rate it Strong Buy with $17.17 avg. target, 44.5% upside. Key questions: ABCL635 timelines, partnership revenue, and pipeline updates.

investing.com
$IOVAMedAI 8/10

Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.

rttnews.com